Novo Nordisk A/S (NYSE:NVO) Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 12.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 484,586 shares of the company’s stock after selling 71,214 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Novo Nordisk A/S were worth $57,713,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. International Assets Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC boosted its stake in Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after buying an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd purchased a new stake in Novo Nordisk A/S in the 3rd quarter valued at $98,765,000. Marshall Wace LLP increased its stake in shares of Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after acquiring an additional 689,441 shares during the last quarter. Finally, Sanctuary Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter worth $41,646,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NVO. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $106.80 on Friday. The firm has a 50-day simple moving average of $112.81 and a two-hundred day simple moving average of $128.00. The stock has a market cap of $479.27 billion, a PE ratio of 34.56, a P/E/G ratio of 1.37 and a beta of 0.42. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.